Attenuated *Salmonella typhimurium* cancer therapy has direct effects on the tumor epithelium in colorectal cancer

Authors: Kendle M. Maslowski^{1,2*}, Masumi Takahashi¹, Yumiko Nakanishi^{1,3,4}, Gillian M. Mackie², Isabel Everard², Alastair Copland², Hirotsugu Oda^{5,6}, Takashi Kanaya^{1,3}, and Hiroshi Ohno^{1,3,4}

Affiliations:

¹ Laboratory for Intestinal Ecosystem. RIKEN Institute for Integrative Medical Science. Yokohama, Japan.

² University of Birmingham, Institute of Immunology and Immunotherapy and Institute of Metabolism and Systems Research, UK.

³ Intestinal Microbiota Project, Kanagawa Institute of Industrial Science and Technology. Kawasaki, Japan.

⁴ Immunobiology Laboratory, Graduate School of Medical Life Science, Yokohama City University. Yokohama, Japan.

⁵ Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 2300045, Japan.

⁶ Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Building 10, Room B3-4129, Bethesda, MD 20892, USA.

*To whom correspondence should be addressed. Email: k.m.maslowski@bham.ac.uk.

One Sentence Summary:

Attenuated *Salmonella enterica* serovar Typhimurium can home to gastrointestinal tumors and directly affect the tumor epithelium, inducing transcriptional and metabolic changes that lead to reduced tumor burden in mice.

Abstract:

Bacterial cancer therapy (BCT) shows great promise for treatment of solid tumors, yet basic mechanisms of bacterial-induced tumor suppression remain undefined. The intestinal epithelium is the natural route of infection for *Salmonella* and thus harbors innate immune defenses which protect against infection. Attenuated strains of *Salmonella enterica* serovar Typhimurium (STm) have commonly been used in mouse models of BCT, largely with the use of xenograft and orthotopic transplant cancer models. We aimed to better understand the tumor epithelium-targeted mechanisms of BCT by using mouse models of intestinal tumorigenesis and tumor organoid cultures to assess the effectiveness and mechanisms of treatment with aromatase A-deficient STm ($STm^{\Delta aroA}$). $STm^{\Delta aroA}$ delivered by oral gavage could significantly reduce tumor burden and tumor load in both a colitis-associated colon cancer model (CAC) and in a spontaneous intestinal cancer model, $Apc^{min/+}$ mice. $STm^{\Delta aroA}$ colonization of tumors caused alterations in transcription of mRNAs associated with epithelial–mesenchymal transition as well as metabolic and cell cycle-related transcripts. Metabolomic analysis of tumors demonstrated alteration in the metabolic environment of $STm^{\Delta aroA}$ -treated tumors, suggesting $STm^{\Delta aroA}$ imposes metabolic competition on the tumor. Use of tumor organoid cultures *in vitro* demonstrated that $STm^{\Delta aroA}$ can directly affect the tumor epithelium with alterations in transcripts and metabolites similar to *in vivo*-treated tumors. Thereby, we demonstrate that bacterial cancer therapy is efficacious in autochthonous intestinal cancer models, that BCT imposes metabolic competition, and that BCT has direct effects on the tumor epithelium, which have not previously been appreciated.

Introduction

The concept of using bacteria as cancer therapeutics (bacterial cancer therapy, BCT) dates back to the late 1800's, when the field of BCT was initiated by William Coley (1). Even earlier observations of spontaneous tumor regression following infection of patients' tumors had led Coley to treat cancer patients with injections of bacterial preparations. Despite this early work on BCT there is only one currently in the clinic; Bacillus Calmette–Guérin vaccine (BCG) therapy for superficial bladder cancer (2). The advancement of molecular genetics and genetic engineering has enabled bacteria to be effectively attenuated to remove adverse side-effects and engineered to deliver different payloads. With this, there has been a resurgence in interest in BCT in the past 20 years, with many studies showing efficacy of attenuated bacterial treatments in xenograft and orthotopic transplant tumor models, with *Salmonella enterica* serovar Typhimurium (STm) being by far the most studied (3–9). Yet despite this interest, very little is understood about the underlying mechanisms of BCT-mediated tumor suppression, which is holding back its practical application. A few phase I trials have been conducted using attenuated STm strains and showed mixed results in terms of colonization and effect (10–12). The STm strain VNP20009 was used in these trials, and when given i.v. showed poor tumor colonization and induced toxicity (10). Another of the trials used intratumoral delivery of VNP20009, and higher tumor colonization was observed without toxicity (11). Lack of chemotactic ability of the VNP20009 strain, due to mutation of the *cheY* gene, has been suggested to be a limiting factor to its success. Mouse models have shown *cheY* to be redundant (13), while another has shown it to be important, for tumor localization (14).

Despite poor translation into the clinic as yet, data from mouse models, as well as Coley's work and the use of BCG therapy, does suggest promise for BCTs. Attenuated STm are extremely tumor-tropic—a therapy that can give such tumor tissue selectivity is very desirable and enables further engineering to deliver drugs, immune adjuvants or other anti-

tumor agents (3). Therefore, further investigation and understanding is warranted. Tumor tissue tropism of attenuated bacteria is thought to be driven by the lack of immune detection within tumors and also the metabolic environment. A benefit of using *STm* is that it is a facultative anaerobe, which means it can reside in both anoxic and aerobic regions of tumor. Recruitment and/or retainment of *STm* in the tumor environment has been suggested to be driven by availability of metabolites. High levels of aspartate, serine, ribose/galactose and ethanolamine have been shown to play a role in different *in vitro* and *in vivo* cancer models (14, 15). The role of chemotaxis is contested, with results suggesting it to be both important and redundant (13, 14, 16). Crull *et al* (16) hypothesized that tumor invasion *in vivo* is more passive than *in vitro*, as the resulting chemokine and cytokine release upon i.v. or i.p. delivery of *STm* would open tumor vasculature enabling delivery of bacteria to the tumor. Therefore, the delivery route and tumor type might account for varying results. It appears that invasion of tumor cells is not necessary for anti-tumor effects, as mutants of invasion genes (eg. SPI-1 and SPI-2) are equally good at invading tumor tissue and inducing tumor regression (14, 16). One study showed the formation of *STm* biofilms within tumors, which was important for their anti-tumor effects (17). It may well be that the tumor model and mode of delivery play a large role in the requirements of *STm*, or other bacteria, to home to tissue.

BCT is assumed to exert its effect by eliciting an immune response. Yet there isn't a clear understanding of immune-mediated events, whether an immune response is elicited to the bacteria, or to tumor cells. It is thought that attenuated *STm*, or other bacteria, can survive within tumors because there is poor immune response (3). Effective treatment with *STm* has been observed in adaptive immune-deficient (nude) mouse models (8, 18), suggesting that T cell responses may not be essential for anti-tumor effects. In some studies that have assessed immune infiltrates, only *STm* or *E. coli* that were engineered to deliver an immune-stimulatory product elicited a significant immune response (19, 20). Other studies have

shown induction of an immune response, such as induction of IL-1 β and TNF- α when delivered i.v. (21, 22) or increased neutrophil and CD8 T cell recruitment when delivered orally (9) to mice bearing subcutaneous tumors (CT26 or MC38 colorectal tumors). So, whilst there is some evidence of changes in tumor immune responses following BCT, it is not yet known whether this is key to the anti-tumor effects of BCT.

The hypothesis that we aimed to explore here is that BCT can have a direct effect on the tumor epithelial cells. Interestingly, the only current BCT in the clinic, BCG used for superficial bladder cancer (2), is delivered intravesically directly to the bladder epithelium, which might be important for its success. Studies on BCT so far have utilized xenograft or orthotopic transplant models of cancer, which may not fully model complex disease in patients and therefore not inform on the mechanisms of BCT. Driven by an interest in intestinal epithelial innate immune pathways that protect epithelial cells from *STm* infection and tumorigenesis (24, 25), we aimed to determine if *STm* treatment could be effective for treating autochthonous tumors of the intestine. We reasoned that since *STm* naturally infects via the intestine, that intestinal cancer would be a good model to use, and that treating colorectal cancer (CRC) patients by oral delivery of attenuated *STm* would be feasible, since oral vaccines for *S. typhi* are widely used and tolerated (26). Oral delivery of *STm* may also avoid problems of tumor homing and toxicity that have been observed when delivering *STm* i.v. to patients (10). Using a model of colitis-associated cancer (CAC) and a spontaneous model of intestinal cancer, *Apc*^{min/+} mice, we showed that oral delivery of an attenuated *STm* reduces tumor burden. Transcriptomic and metabolomic analysis, coupled with use of tumor organoids *in vitro*, demonstrated effects of *STm* on the tumor epithelium, and found that metabolic competition was a likely driver of anti-tumor effects.

Results

Orally-administered aromatase-A-deficient *STm* reduces gastrointestinal tumor burden

We utilized *STm* deficient for aromatase A (*STm^{ΔaroA}*) (UF020 (27)) to assess whether BCT could be effective for treating murine autochthonous gastrointestinal tumors (colon or small intestine (SI)). We first induced colon tumors in C57B6/J mice using a well-described model of colitis-associated cancer (CAC), which has 100% penetrance (25, 28) (**Fig. 1A**). After tumor induction, mice were then split into treatment groups, ensuring equivalent colitis severity between groups. **Fig. S1** shows weight loss during the AOM/DSS protocol. After recovery from the final dose of DSS, mice were given 5×10^9 CFU *STm^{ΔaroA}*, or vehicle control, by oral gavage once per week for 6 weeks. After 6 weeks treatment, tumor burden was assessed and compared to that of control-treated mice and to mice sacrificed at the start of the *STm^{ΔaroA}* treatment protocol (denoted D0) (**Fig. 1A**). Tumor burden and tumor load was significantly decreased in *STm^{ΔaroA}*-treated mice, compared to D0 and 6-week control-treated mice (**Fig. 1B**). This indicates that *STm^{ΔaroA}* treatment by oral delivery could reduce existing tumor burden and prevent further tumor development or growth.

Next, we tested *STm^{ΔaroA}* treatment in *Apc^{min/+}* mice. These mice carry a mutation in the adenomatous polyposis coli gene (*Apc*) which results in multiple intestinal neoplasia (min), serving as a model of human familial adenomatous polyposis (FAP). Though, in mice the *Apc* mutation results largely in small intestinal (SI) neoplasia, and not colonic neoplasia. We treated *Apc^{min/+}* mice with 5×10^9 CFU *STm^{ΔaroA}* by oral gavage once per week for 10 weeks, from 8 weeks of age (**Fig. 1C**). At this age, the SI has already developed a large number of polyps and they continue to grow in size, with mice at 18 weeks showing large well-developed polyps throughout the SI tract. Treatment of *Apc^{min/+}* mice with *STm^{ΔaroA}* substantially reduced the tumor burden and tumor size (**Fig. 1D**).

Figure 1: Oral delivery of attenuated *STm* reduces intestinal tumor burden.

(A) Schematic of AOM/DSS induced CAC model and *STm*^{ΔaroA} treatment. (B) Tumor burden (# tumors / mouse) and tumor load (cumulative tumor size per mouse, mm²) in non-treated (nt) and *STm*^{ΔaroA}-treated mice. N=5 for D0 and nt groups and N=9 for *STm*^{ΔaroA}-treated mice. Representative of 4 independent experiments. Female mice were used in this experiment, male mice also showed same response. (C) Schematic of *Apc*^{min/+} mouse *STm*^{ΔaroA} treatment. (D) Tumor burden and tumor size per mouse in non-treated (nt) and *STm*^{ΔaroA}-treated mice. Data pooled from 2 independent experiments using both male and female mice, nt N=8 (4F, 4M), *STm*^{ΔaroA}-treated N=9 (5F, 4M). (E-F) colony forming units (CFU) of *STm*^{ΔaroA} in normal (N) and tumor (T) tissue from *STm*^{ΔaroA} treated mice in the CAC and *Apc*^{min/+} models, respectively. One-way ANOVA (B, D) or two-way T-test (D) were used.

***STm*^{ΔaroA} specifically localize in tumor tissue**

Attenuated strains of *STm* preferentially home to tumor tissues and not to normal healthy tissues (4–9) and hence do not cause overt disease in recipient mice. We confirmed that *STm*^{ΔaroA} could be re-isolated from tumor tissue, but not from normal healthy tissue surrounding the tumors in both the CAC and *Apc*^{min/+} models (**Fig. 1E and F**, respectively). Further, we checked whether *STm*^{ΔaroA} could disseminate to peripheral organs 24 hours after infection of *Apc*^{min/+} mice and could find very few or no CFU in the blood, MLN, liver or spleen (**Fig. S2**).

We next employed scanning electron microscopy (SEM) to view bacterial colonization in greater detail. We found exceptionally large colonies of *STm*^{ΔaroA} within the tumor mass just 24 hrs after administration (**Fig. 2**, see insets). The large size of the bundles suggest that they were rapidly dividing within the tumor extracellular spaces. We could also find instances of single or a few bacteria (**Fig. 2**, red arrows). No bacteria could be observed in non-treated mice (**Fig. S3**), suggesting that normal microbiota are not able to penetrate tumor tissue to form mass colonies as observed with the *STm*^{ΔaroA}. Immunohistochemistry detecting mCherry-expressing *STm*^{ΔaroA} further supports the SEM data showing large colonies of *STm*^{ΔaroA} (**Fig. S3**).

Figure 2: Scanning electron microscopy of *STm*^{ΔaroA}-treated tumors.

Mice bearing CAC colon tumors were given *STm*^{ΔaroA} or control vehicle by oral gavage and tissues were taken 24 hours later. Whole sections of colon with tumors were prepared for SEM by glutaraldehyde fixation, dehydration and freeze drying. Tumors were cut on the sagittal plane and mounted for platinum-coating and SEM imaging. Top image shows lower magnification view of a tumor area. Luminal side indicates the top of the tumor that was facing the intestinal lumen and muscularis side indicates the inner side of tumor reaching the lamina propria and muscularis mucosa. Small red arrows indicate small *STm*^{ΔaroA} colonies or individual bacteria. Large black arrows indicate areas shown in higher magnification shown below.

***STm*^{ΔaroA} alters the transcriptional landscape of tumors**

Next, to gain an understanding of the differences between non-treated and *STm*^{ΔaroA}-treated tumors, we performed RNA sequencing on RNA isolated from whole tumor homogenates. Tumor (T) and adjacent normal (N) tissue was dissected from AOM/DSS-induced CAC-bearing mice after 4 weeks treatment. First, we identified the transcripts that were differentially regulated between N and T tissue in the non-treated and *STm*^{ΔaroA}-treated

groups. **Fig 3A** shows the number of overlapping and unique genes for each treatment. These differentially-expressed genes (DEGs) were then analyzed by gene ontology (GO) analysis using DAVID (29, 30), revealing terms enriched in either the non-treated tumors or in the treated tumors, which intriguingly were vastly different (**Fig. 3B**). As expected, non-treated tumors exhibited enrichment of mRNAs involved in cell cycle processes, mitosis, cell division, DNA repair etc., whereas, *STm* ^{Δ aroA}-treated tumors displayed enrichment of mRNAs for processes involving regulation of mesenchymal cell proliferation, mesenchymal-epithelial cell signaling, as well as regulation of blood vessel development, amongst other pathways. (**Fig. 3B, Fig. S4**).

Figure 3: *STm* ^{Δ aroA} treatment alters the transcriptional landscape of tumors.

Normal and tumor tissue were dissected from CAC-bearing mice after 4 weeks of *STm* ^{Δ aroA} or control treatment and RNA isolated and used for RNA sequencing analysis. (**A**) # of transcripts upregulated or downregulated in tumor compared to normal tissue, with overlapping and unique transcripts depicted. (**B**) Differentially expressed genes (DEGs) in tumors compared to normal tissue for each treatment identified in (A) were compared by GO analysis. Data represents the % of genes of a given pathway that are enriched in either non-treated or treated tumors, with -log p-value.

Several genes involved in DNA repair, DNA damage response, RNA synthesis and epithelial-mesenchymal transition were significantly reduced following *STm^{ΔaroA}* treatment (**Fig. S4**), which suggest a change in rate of cell proliferation. We decided to concentrate on stem cell, EMT and metabolism-related genes, and confirmed a selection of targets by qPCR in independent experiments. As previously reported, transcripts for epithelial stem cells, proliferation or epithelial-to-mesenchymal transition-related processes, including *Lgr5* (leucine-rich repeat-containing G-protein coupled receptor), *Smoc2* (SPARC related modular calcium binding 2), *Vim* (Vimentin), *Ccnd1* (Cyclin D1) and *Pdk4* (pyruvate dehydrogenase kinase 4) (31–37) were increased in tumor tissue when compared to normal tissue (**Fig. 4A**). Strikingly, these transcripts were largely decreased following *STm^{ΔaroA}* treatment (**Fig. 4A**). We confirmed these mRNA changes in the *Apc^{min/+}* model, comparing tumor tissue from non-treated and *STm^{ΔaroA}* treatment. In line with results from the CAC model, *STm^{ΔaroA}* treatment altered the transcriptional levels of the above-mentioned genes and additional EMT-related genes *Twist* and *Snail* (**Fig. 4B**). Loss of E-cadherin protein at the cell-cell junctions is an important feature of EMT, therefore we checked E-cadherin protein expression and localization by immunofluorescent staining of sections taken from CAC tumor-bearing mice. Non-treated tumor sections showed very little E-cadherin protein; and where it was present it was cytosolic staining (**Fig. 4C**). In contrast, tumors from *STm^{ΔaroA}* treated mice showed significant levels of cell membrane localized E-cadherin (**Fig. 4C**). Thus it appears that *STm^{ΔaroA}* treatment diminishes tumors and restores epithelial identity. This likely reflects that *STm^{ΔaroA}* treatment is having a direct effect on tumor cells as well as the fact that tumors are diminished in size and normal epithelium is restored.

Figure 4: Altered tumor phenotype in *STm* $^{\Delta aroA}$ treated mice.

(A) qPCR confirmation of genes identified (or pathway related) by RNAseq in CAC-tumor bearing mice after 6 weeks treatment. Non-treated (NT), Salmonella treated (*STm* $^{\Delta aroA}$), normal tissue = N, tumor tissue = T. Data representative of 4 independent experiments. One-way ANOVA with Turkey's multiple comparisons test was conducted. ANOVA P-values are indicated below the graphs and individual post-test comparing T from each treatment is shown on the graphs. (B) Analysis of indicated transcripts in *Apc* $^{min/+}$ tumor tissue after 10 weeks treatment. Data representative of 2 independent experiments. NT N = 3, *STm* $^{\Delta aroA}$ N=4. Unpaired two-way T-tests were used. (C) Immunofluorescence of E-cadherin (red) counterstained with DAPI (blue) in NT and *STm* $^{\Delta aroA}$ -treated CAC mice.

***STm*^{ΔaroA} alters the metabolic environment of tumors**

Previous studies have demonstrated that BCT can affect tumor growth by utilizing excess nutrients, such as ethanolamine (14), or are attracted to tumors due to high levels of metabolites, such as ribose or leucine (15). Our observation of large intra-tumoral, extracellular *STm*^{ΔaroA} colonies led us to question whether the tumor metabolome would be altered following treatment, as the bacteria would be competing for metabolites within the tumor environment. Tumor and normal tissue from non-treated or *STm*^{ΔaroA}-treated CAC-tumor bearing mice after 6 weeks or 24 hours treatment were analyzed by GC-MS for polar-metabolites. Unit variance (UV) scaled GC-MS data was analyzed, and Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) plots revealed a separation between non-treated and treated tumors after 6 weeks and also within 24 hours (**Fig. 5A, B** respectively) (6 weeks treatment in vivo: $R^2 = 0.99$; $Q^2 = 0.52$; 24 hours treatment in vivo: $R^2 = 0.99$; $Q^2 = 0.67$). We performed pathway analysis on metabolites with a variable importance on the projection (VIP) score greater than 1 using MetaboAnalyst 3.0 (3, 4) (**Tables S1 and S2** show the complete list). Common pathways affected by *STm*^{ΔaroA} treatment at both timepoints (6 hours and 24 hrs) included glycine, serine and threonine metabolism, arginine and proline metabolism and citric acid cycle, amongst others (**Fig. 5C,D**). As previously described (40), many metabolites, and particularly amino acids and tricarboxylic acid (TCA) cycle intermediates, are increased in tumor tissue compared to normal tissue (**Fig. 5E, Fig. S5 & 6**). This likely reflects the increased energy and anabolic requirements of tumors. Strikingly, many metabolites were decreased following *STm*^{ΔaroA} treatment. **Fig 5E** shows metabolites detected in glycolysis and the TCA cycle, as well as amino acids. Perhaps not surprisingly, glucose was significantly reduced in *STm*^{ΔaroA} treated tumors (**Fig 5E**). Other glycolysis intermediates were only mildly affected, while several TCA cycle intermediates (citrate, succinate, fumarate and malate) were reduced following treatment. (**Fig 5E**). Furthermore, several amino acids, which can feed different parts of the TCA cycle were reduced, including

glutamate (glutamine was not detected) (**Fig 5E**), which is an important fuel for glutaminolysis for which tumors can be quite dependent (41).

Other important oncometabolites were also affected. The polyamine synthesis pathway appears affected at both 24 hours and 6 weeks post-treatment. Ornithine was reduced in *STm^{ΔaroA}* treated tumors 24 hours and 6 weeks post-treatment, while putrescine was significantly affected after 6 weeks treatment and spermidine after 24 hours (**Fig. S5 & 6**). 2-hydroxyglutarate (2-HG) can accumulate in tumors due to mutant isocitrate dehydrogenase 1/2 (IDH2) activity, converting α -ketoglutarate (α -KG) to 2-HG, which can inhibit α -KG-dependent dioxygenases, leading to increased histone and DNA methylation (41). We saw increased 2-HG in CAC tumors, and this was decreased after 24 hours treatment (**Fig. 5E**). Thus, several important fuel sources, metabolic intermediates and oncometabolites are decreased following *STm^{ΔaroA}* treatment, assumedly through metabolic competition of the bacteria on the tumor cells.

Figure 5: *STm*^{ΔaroA} treatment alters the metabolic environment of tumors.

Tumor metabolites were assessed by GC-MS. OPLS analysis of metabolites comparing non-treated (NT) and *STm*^{ΔaroA} treated tumors after (A) 6 weeks and (B) 24 hours treatment. All metabolites significantly different between *STm*^{ΔaroA} treated and non-treated tumors (VIP score>1) were submitted to pathway analysis (MetaboAnalyst). Pathway analysis for 6 weeks *STm*^{ΔaroA} treatment (C) and 24 hours treatment (D), represented as the percent of metabolites in a pathway that were altered, against p-value (-log). (E) Metabolites detected from glycolysis (pink shading) and TCA cycle (green shading), and amino acids (orange shading), with interrelationships depicted. X-axis are nmol/g. One-way ANOVA was performed with Bonferroni multiple comparisons test, P-values shown are the multiple comparison statistic.

***STm*^{ΔaroA} directly affects tumor epithelium**

Our initial hypothesis was that BCT would have a direct effect on tumor epithelium. The effects that we have described so far on tumor stem cell markers, an increase in epithelial identity, and a change in the tumor metabolome in *STm*^{ΔaroA} treated tumors, suggests an impact of *STm*^{ΔaroA} treatment on tumor cells. To directly test our hypothesis that *STm*^{ΔaroA} treatment has a direct effect on tumor epithelium, we utilized tumor 3D organoid cultures. We generated organoid lines from CAC-induced colorectal tumors and from *Apc*^{min/+} SI and colonic tumors. Representative images of organoid appearance is shown in **Fig. S8A-C**. Tumor organoids were infected with *STm*^{ΔaroA} by inoculating the culture medium (1x10⁸ CFU). *STm*^{ΔaroA} were able to invade the Matrigel and infect the organoids (**Fig. 6A&B**). After 2 hrs infection, the culture medium was washed off and fresh medium containing gentamycin was added, so only bacteria that had infected organoids could grow, preventing any effects purely from bacterial over-growth. Organoids were then collected for analysis 24 hours after the initial infection. CFU analysis was performed to determine bacterial burden. We observe in the order of 1x10⁵ CFU (**Fig. 6B**) per well, which contains around 1x10⁶ cells within the organoid structures. Importantly, treatment of organoids with *STm*^{ΔaroA} could recapitulate effects on gene expression seen *in vivo*, with a substantial reduction in transcripts for *Lgr5*, *Smoc2* and *Vim* in both CAC-derived and *Apc*^{min/+}-derived tumor organoids, and *Pdk4* in *Apc*^{min/+} organoids (expression was very low in CAC organoids) (**Fig. 6C and D**). These results provide evidence that *STm*^{ΔaroA} treatment can directly affect the tumor cells,

independent of effects on other systems/cell types such as the immune system. Furthermore, analysis of the organoid metabolome demonstrated separation of non-treated and treated organoids by OPLS analysis (**Fig. 6E**). Taking all metabolites with a VIP score >1 (**Table S3**) and analyzing by MetaboAnalyst revealed similarly affected metabolic pathways following *in vitro* *STm*^{ΔaroA} treatment as for *in vivo* treatment, with amino acid metabolism pathways, TCA cycle and glycolysis being altered (**Fig. 6F, Fig. S7**). These data suggest that bacterial colonization imposes direct metabolic competition.

To further dissect whether live bacteria are required to mediate the observed effects of *STm*^{ΔaroA} on tumor organoids, or whether the presence of heat-killed bacteria or just the bacterial supernatant would be sufficient, we compared treatment of tumor organoids with live *STm*^{ΔaroA}, heat-killed *STm*^{ΔaroA} or *STm*^{ΔaroA} supernatant (SN, prepared using 10 kDa exclusion columns). Live bacteria had the strongest effect on reducing stem cell and EMT marker expression (**Fig. 6G**). Heat-killed bacteria induced a slight reduction in *Smoc2* and *Vim*, while *STm*^{ΔaroA} SN had no effect (**Fig. 6G**), suggesting that secreted products from bacteria are not exerting these anti-tumor effects, and bacterial ligands (eg LPS) are also not driving these responses (note 10kDa filters exclude LPS, **Fig. S8D**). Furthermore, succinate, one of the metabolites identified as being reduced by *STm*^{ΔaroA} treatment *in vivo*, was assayed and only live *STm*^{ΔaroA} could induce a reduction (**Fig. 6H**), thus further supporting the idea that *STm*^{ΔaroA} directly impose metabolic competition.

Figure 6: *In vitro* treatment of tumor-derived organoids with *STm*^{ΔaroA}.

Tumor organoids derived from CAC-induced tumors and *Apc*^{min/+} tumors were established and infected with mCherry-expressing *STm*^{ΔaroA} for 24 hrs. (A) Brightfield and fluorescent microscope images of organoids within matrigel after 24 hrs infection, shows association of *STm*^{ΔaroA} with tumor organoids and the appearance of bursting. (B) CFU of *STm*^{ΔaroA} per well after 24 hrs infection. qPCR analysis of the indicated transcripts in (C) CAC-derived and (D) *Apc*^{min/+} tumor organoids. Representative of >3 independent experiments with 4 independently-derived organoid lines, with between 3 and 5 technical replicates per experiment. Tumor organoid metabolites were assessed by GC-MS, (E) OPLS-DA analysis and (F) pathway analysis of metabolites with a VIP score >1. (G) CAC-derived tumor organoids were cultured with live or heat-killed (dead) *STm*^{ΔaroA}, or with supernatant (SN) of *STm*^{ΔaroA} grown in organoid culture medium and the indicated mRNA's analyzed by qPCR. (H) analysis of succinate levels in tumor organoids treated as described in (G). Individual two-way T-tests (C&D) or Kruskal-Wallis tests (G-H) were performed.

Discussion

Here, we present data showing that BCT can be efficacious in autochthonous models of intestinal cancer. Oral delivery of *STm* ^{Δ aroA} to colonic or SI tumor-bearing mice induced a reduction in tumor number and size. While the concept of using bacteria as cancer therapeutic agents is by no means novel, attempts at mechanistic understanding using *in situ* cancer models has not been attempted before. Previous studies have utilized orthotopic or xenograft transplant tumor models, which may not fully recapitulate complex tumor environments in spontaneously formed tumors. Therefore, to start to unpick mechanisms of BCT action, using tumor models that more faithfully recapitulate tumor development may be necessary. Apart from one BCT in the clinic (BCG used for superficial bladder cancer), trials using attenuated *STm* have not been successful. In a phase 1 trials, giving heavily attenuated *STm* intravenously resulted in poor tumor localization (10), whereas another small trial giving bacteria by intratumoral injection had better tumor localization (11). BCG therapy is given directly onto the bladder epithelium. This suggests that the future of BCT may be where it can be applied more locally. Oral delivery of an attenuated *STm* would be feasible, and enable delivery directly to colonic tumors, avoiding toxicity overserved with i.v.-delivered bacteria. Proof-of principle on tolerance and safety of such treatment can be seen with *S. Typhi* vaccination (26).

Previous studies have shown that *STm* genes involved in ethanolamine catabolism were essential for *STm* survival within tumors (14), and that *STm* utilize nutrient sensing pathways to localize to tumors (15). We demonstrate that *STm* ^{Δ aroA} form large intra-tumoral colonies and drastically re-shape the tumor metabolome within 24 hours. Multiple metabolic pathways were affected by *STm* ^{Δ aroA} treatment, which would impose strong metabolic pressure on tumors cells, which would possibly make it more difficult for tumors to switch from one pathway to another to meet energy and anabolic requirements. Importantly, these biochemical

effects were not seen in surrounded normal tissue. Drugging tumor metabolism is an important avenue for cancer therapy, with standard chemotherapies taking advantage of metabolic weaknesses (41). However, not all tumors are susceptible, and side-effects from inhibiting all fast-dividing cells limits metabolic inhibitor usage. Further, some tumors are able to metabolically adapt if one pathway is blocked (41). BCT may therefore be an avenue for introducing metabolic competition, coupling this with other metabolic inhibitors may enable lower doses of these drugs that may otherwise cause severe side-effects.

The data presented here shows bulk metabolites from tumors that contain *STm^{ΔaroA}*, so we can't decipher which metabolites are bacterial-derived and which are host-derived, but the observed decrease in many metabolites from multiple pathways implies that *STm^{ΔaroA}* utilize tumor-derived metabolites. Wildtype *STm* have been reported to utilize succinate and lactate within the intestinal environment (42, 43), and we found a reduction of succinate *in vitro* only when live *STm^{ΔaroA}* were present, suggesting active use of tumor metabolites by *STm^{ΔaroA}*. It is possible that the metabolic competition also induces a shift in the tumor metabolism. We observed changes in *Pdk4*, a metabolic gene involved in inhibiting pyruvate entering into the TCA cycle. Down-regulation of this following *STm^{ΔaroA}* may represent the tumor altering metabolism to reflect the change in available metabolites, or could be a result of reduction of other metabolites such as succinate, which would cause less HIF1α stabilization and reduced phosphorylation and activation of *Pdk4*.

Importantly, we have shown here that *STm^{ΔaroA}* can directly affect tumor cells, a feature that hasn't previously been appreciated. That *STm^{ΔaroA}* reduced stem cell markers is promising as remaining tumor stem cells are able to form relapsing disease. Whether the effect of *STm^{ΔaroA}* on stem cells marker expression was due to *STm^{ΔaroA}* being more tropic for stem cells or that

stem cells are more susceptible to metabolic pressure isn't yet clear. There are likely numerous concurrent adaptations occurring, and the data presented here provide some new suggestions of how BCT may be effective.

Several groups are taking the approach to BCT to engineer the bacteria to deliver drugs or other compounds that can further promote tumor death or immune clearance (19, 20, 44–47). Given that bacteria home specifically to tumors, they are the ideal device to use to ensure tumor-specific drug targeting (3). The data we present here shows that BCT does induce tumor regression in autochthonous models of cancer, and we show strong effects on the tumor metabolome and transcriptome. Though it is apparent that *STm*^{ΔaroA} alone does not cure the mice, so further engineering of the bacteria, and/or co-therapies, are required. By understanding the mechanisms of action we could further improve the engineering of bacteria for BCT, for example delivering an engineered bacteria that can better utilize metabolites. Or unpicking how BCT affect stem cell transcripts may lead to clues on how to better target tumor stem cells. Furthermore, rational selection of tumor types and stages to be targeted, type of bacteria and attenuations, and delivery route are all likely to be important for the success of BCT. This paper demonstrates that CRC is an excellent candidate for targeting with BCT via oral delivery of attenuated *STm*.

Materials and Methods

Animals

C57B/6J mice were purchased from JAX or CLEA (Japan). *Apc*^{min/+} mice were purchased from JAX (<https://www.jax.org/strain/002020>). Animal breeding was conducted under specific pathogen-free conditions at the RIKEN Center for Integrative Medical Sciences Animal Facility and infection experiments were conducted at the conventional facility at Yokohama City University. 12 hr day/night cycles (7am-7pm in both facilities) and chow and

water were fed *ad libitum*. All animal experiments were approved by the Institutional Animal Care and Use Committees of RIKEN Yokohama Branch and Yokohama City University.

Colitis-associated cancer model

C57B6/J mice were purchased at 6 weeks of age and allowed settle into the mouse facility for 1-2 weeks. Starting at 7 to 8 weeks of age, mice were given one i.p. injection of AOM (10 mg/kg, Sigma) in the afternoon. The following day, mice were given DSS (1%, MW 35 000-50 000, MP Biochemicals) in the drinking water for 5 days, followed by 16 days normal water. 2 more doses of DSS (1%) were given for 5 day periods. After the 3rd DSS dose, mice recovered for 1 to 2 weeks before starting the *STm*^{ΔaroA} treatment.

Apc^{min/+} model

Wild-type C57B/6J female mice were bred with heterozygote *Apc*^{min/+} males. Litters were weaned at 4 weeks of age and genotype confirmed. *Apc*^{min/+} mice (male and female) were transferred to the experimental facility at 6 weeks of age, and *STm*^{ΔaroA} treatment started at 8 weeks. At the end of the protocol, genotypes were re-confirmed.

STm^{ΔaroA} treatment

UF020 *Salmonella* typhimurium strain lacking aromatase A (27) was grown overnight in LB broth with ampicillin (200 ug/mL). In the morning a 1:20 subculture was grown in LB broth (no ampicillin) to an OD₆₀₀ of 0.7 to 0.8 OD₆₀₀ = 5x10⁵ CFU/mL). Cultures were centrifuged (4000 rpm, 8 mins, room temperature) and washed twice in PBS before resuspending at 5x10⁹ CFU per 100 uL. This was transferred to the animal facility within 30 minutes and mice were delivered 100 uL by oral gavage at the indicated time points.

Tissue isolation and analysis

At the end of the *STm*^{ΔaroA} treatment, mice were killed and colons (CAC) or SI (*Apc*^{min/+}) were dissected out, cut longitudinally and washed thoroughly in cold PBS. Tumors were counted under a stereo microscope using an eyepiece graticule with 10x10 mm grid. Tumors and normal tissue were then micro-dissected and either snap frozen in liquid N₂ for later analysis or used for assessing bacterial colonization (CFU).

Colony forming unit analysis

Tissue was homogenized in PBS containing 0.1% triton-X using a hand-held homogenizer. After serial dilution, 50 uL was plated onto LB agar plates containing ampicillin (200 ug/mL)

and incubated at 37°C overnight. Colonies were counted and CFU calculated per gram of tissue.

Scanning electron microscopy

Colons were dissected out, cut longitudinally and thoroughly washed in PBS. Sections around 1 cm were cut and fixed in 2.5% glutaraldehyde in 0.1% phosphate buffer for 24 hours at 4°C. Tissue was then dehydrated in increasing concentration of ethanol (50% -> 70% -> 80% -> 90% -> 95%-> 100% -> 100%) for 15 minutes each, then tissues substituted with t-butyl alcohol followed by freeze drying. Before mounting samples, tumors were cut on the sagittal plane to reveal the tumor core then mounted onto aluminum stubs and were metal-coated using a magnetron sputter (MSP-1S; Vacuum Device), and examined by scanning electron microscopy (VE-7800; Keyence).

RNA isolation

RNA was isolated using Qiagen RNeasy Mini kits, as per manufacturer instructions. Briefly, tissue stored in -80°C was placed in buffer RLT + β -mercaptoethanol and homogenized by bead beating. Lysates were then processed as recommended, with the optional DNase digest. RNA was quantified using a DeNovix DS-11.

cDNA library prep and RNA sequencing

RNA integrity was assessed by Agilent Bioanalyzer before proceeding RIN values of 8 or greater were used. 2 ug of RNA was used to prepare a cDNA library using TruSeq RNA Library Prep Kit v2 (Illumina). Sequencing was performed on an Illumina HiSeq 1500 System in a 1 x 50 bp single read mode. Sequenced reads were mapped against the mouse reference genome (mm10) using TopHat (48), and gene expression was quantified by Cufflinks (49). Gene ontology enrichment analysis was performed using DAVID (29, 30). The original RNAseq data is uploaded and available online (Gene Expression Omnibus: GSE136029).

cDNA prep and qPCR

cDNA was prepared using standard oligoDT and M-MLV reverse transcriptase. Quantitative real-time PCR was performed with the LightCycler® 480 Real-Time PCR System (Roche, Switzerland) and SYBR Premix Ex Taq (Takara). Gene-specific primers (Eurofins Genomics, Japan) are listed in **Table 1**.

Table 1: Primers used for qPCR analysis

Gene name	Sequence fwd	Sequence rev	Species
<i>Pdk4</i>	CCGCTGTCCATGAAGCA	GCAGAAAAGCAAAGGACGTT	mouse
<i>Twist</i>	CGGGTCATGGCTAACGTG	CAGCTTGCCATCTTGGAGTC	mouse
<i>Snail</i>	CCACACTGGTGAGAAGCCATTC	TCTTCACATCCGAGTGGGTTT	mouse
<i>Smoc2</i>	CCCTCAGAAGCCACTCTGTG	ACTTGCTGGAACCTCTCCG	mouse
<i>Vim</i> (Vimentin)	CGGAAAGTGGAATCCTTGCA	CACATCGATCTGGACATGCTGT	mouse
<i>Ccnd1</i> (CyclinD1)	ACCTGCATGTTCTGGCCTCTAAG	CTCATCCGCCTCTGGCATTITG	mouse
<i>Lgr5</i>	CGGAGGAAGCGCTACAGAAT	CTGGGTGGCACGTAGCTGAT	mouse
<i>Gapdh</i>	TGTGTCCGTCGTGGATCTGA	TTGCTGTTGAAGTCGCAGGAG	mouse
<i>18s</i>	GATCCATTGGAGGGCAAGTCT	CCAAGATCCAACCTACGAGCTTTT	mouse

Immunofluorescence

Freshly dissected colon tissue was swiss-rolled and placed in 4% PFA overnight. Samples were paraffin embedded and 5 μ m sections cut. Paraffin sections were rehydrated and washed with PBS. Then, tissues were incubated with 1% BSA/PBS supplemented with 5% normal serum donkey serum to quench the nonspecific binding of antibodies. Goat anti-E-cadherin (R&D Systems, 1:200) was incubated overnight, washed, secondary stain with anti-goat IgG 633 (LifeTechnologies) and counterstained with DAPI. Samples were imaged using Leica AF6000 microscope.

GC-MS analysis of metabolites

Extraction and measurement of metabolites were previously described (50) with some modifications. Tumor and normal intestinal tissues and tumor organoids (approximately 10 mg) were added to 125 μ l methanol, 150 μ l Milli-Q water containing internal standard (100 μ mol/l 2-isopropylmalic acid) and 60 μ l CHCl_3 and disrupted with zirconia beads using Micro Smash MS-100 (Tomy Seiko). All samples were shaken at 1,200 rpm for 30 min at 37°C. After centrifugation at 16,000 $\times$ g for 5 min at room temperature, 250 μ l of the supernatant were transferred to a new tube and 200 μ l of Milli-Q water added. After being mixed, the solution was centrifuged at 16,000 $\times$ g for 5 min at room temperature, and 250 μ l of the supernatant were transferred to a new tube. Samples were evaporated for 20 min at 40°C, and then lyophilized using a freeze dryer. Dried extracts were firstly methoxymated with 40 μ l of 20 mg/ml methoxyamine hydrochloride (Sigma-Aldrich) dissolved in pyridine. After adding the derivatization agent, samples were shaken at 1,200 rpm for 90 min at 30°C. Samples were then silylated with 20 μ l of N-methyl-N-trimethylsilyl-trifluoroacetamide (GL

Science) for 30 min at 37°C with shaking at 1,200 rpm. After derivatization, samples were centrifuged at $16,000 \times g$ for 5 min at room temperature, and the supernatant transferred to glass vial for gas chromatography-tandem mass spectrometry measurement using a GCMS-TQ8030 triple quadrupole mass spectrometer (Shimadzu) with a capillary column (BPX5, SGE Analytical Science). The GC program was previously described (50). Data processing was performed using LabSolutions Insight (Shimadzu).

The quantified metabolome data was statistically analyzed using Orthogonal Partial Least Square-Discriminant Analysis (OPLS-DA) with SIMCAP+ software (Version 12.0.1.0, Umetrics, Umeå, Sweden) using UV scaling method. Potential metabolites were selected based on the Variable Importance in Projection (VIP) score greater than 1.0 and uploaded to MetaboAnalyst 3.0 (<http://www.metaboanalyst.ca>) for pathway analysis. The functional pathway analysis of potential biomarkers was based on the database source of the Kyoto Encyclopedia of Genes and Genomes (<http://www.genome.jp/kegg/>).

Tumor organoid establishment and culture

Tumor organoids were established as previously described (51), with some alterations. Buffers and culture medium components are listed in **Table 2**. Tumors were dissected from the colons of mice that had CAC-induced tumors and from the SI and colon of *Apc^{min/+}* mice. Tumors were washed in cold PBS then incubated in 10 mL chelation buffer with 2mM EDTA for 60 mins on ice. Tubes were shaken vigorously by hand (removes most normal epithelium) and EDTA buffer was removed and tumor tissue then washed 3x with chelation buffer. Tissue was then incubated in digestion buffer for 30 minutes at 37°C with shaking. Supernatant was filtered through a 70 μ M filter, remaining tissue wash once with basic medium and also filtered. Cells were then pelleted (300 g for 3 minutes) washed once then resuspended in Matrigel (Corning 356231) (50 μ L per well) and cultured in 24-well plate with 500 μ L complete medium. Once established for 1 to 2 weeks, cultures were switched to EGF-only medium.

For maintenance, organoids were split every week. In brief, all tubes and tips were pre-coated with FBS, organoids were manually disrupted from the Matrigel using P500 pipette and transferred to a 50 mL Falcon tube. Tubes were centrifuged at 300 g for 5 mins at 4 deg. Excess medium was removed carefully to not removed Matrigel containing the cell pellet. Organoids were resuspended in 4 mL Basic medium, transferred to a 15 mL tube and pipetted thoroughly using a fire-polished glass pipette to break up the organoids. These were centrifuged and resuspended in Matrigel and plated out. Split ratios of around 1:4 to 1:6 depending on density.

Table 2: Intestinal tumor organoid culture reagents

Chelation buffer	in distilled water: <ul style="list-style-type: none"> - 5.6 mmol/L Na₂HPO₄ - 8.0 mmol/L KH₂PO₄ - 96.2 mmol/L NaCl - 1.6 mmol/L KCl - 43.4 mmol/L sucrose - 54.9 mmol/L D-sorbitol - 0.5 mmol/L DL-dithiothreitol (added fresh)
Digestion buffer	DMEM: <ul style="list-style-type: none"> - 2.5% FBS - pen/strep - 400U/mL collagenase D - 25 U/mL Dispase
Basic medium	<ul style="list-style-type: none"> - Advanced DMEM F12 – 500mL (Life Technologies) - Pen/Strep 1:100 - Glutamax – 1:100 - HEPES 1:100
2xN2/B27/NA medium	<ul style="list-style-type: none"> - N2 (200 uL of 100x) - B27 (400 uL of 50x) - NA (50 uL of 500 mM) - Added to 10 mL of Basic medium – use within 1-2 weeks
Complete medium	<ul style="list-style-type: none"> - Basic medium + 2xN2/B27/NA (1:1) - mNoggin. Peprotech Cat#250-38. 1000x stock: 100 ug/mL in 0.1% BSA/PBS. 20 uL aliquots. Store at -20. - mEGF. Peprotech Cat#315-09. 10,000x stock: 500 ug/mL 0.1% BSA/PBS. 5uL aliquots. *before use, add 45uL basic medium to make 1000x solution. - Rspol conditioned medium (CM) 1:20 - CHIR99021 (GSK3 inhibitor). 5mM in DMSO. - Y-27632 (ROCK inhibitor). 10mM in PBS. Use only for recovering frozen stock, or first establishing. <p>Make as you need it, use immediately</p>
Tumor medium	<ul style="list-style-type: none"> - Basic medium + 2xN2/B27/NA (1:1) - mEGF (1:1000) - ROCK inhibitor (Y27632) 1:500 for recovery (not in growth) <p>Make as you need it, use immediately</p>

STm^{ΔaroA} infection of tumor organoids

Tumor organoids were infected at day 5 post-split to ensure good organoid size and integrity. *STm*^{ΔaroA} was grown overnight and sub-cultured as described above. 5 μL containing 1x10⁸ CFU was dropped into the culture medium (or PBS control) and left for 2 hrs to allow for bacterial invasion of the Matrigel and organoids. After 2 hrs medium was removed and Matrigel washed 2x with PBS and medium replaced and gentamycin added. These were cultured overnight and organoids collected 24 hrs after initial infection for analysis. For qPCR analysis, buffer RLT was added directly to the culture plate (after removing medium and washing with PBS) which completely dissolved the Matrigel, these were then processed for RNA isolation as described above. For metabolome and succinate assays, culture medium was removed and the Matrigel washed with PBS. BD Cell Recovery Solution was added and

plate kept on ice for 1 hr to dissolve the Matrigel. Organoids were collected into Eppendorf tubes spun and washed twice with cold PBS. Organoids were then snap frozen and stored at -20 until analysis.

Heat killed *STm*^{ΔaroA} was prepared by incubating at 95°C for 5 minutes. Effective killing was tested by plating out on LB agar. SN was prepared by growing *STm*^{ΔaroA} in tumor culture medium until an OD₆₀₀ of approximately 0.7. SN was filtered with a 10 kDa cut-off columns. 1x10⁵ heat-killed *STm*^{ΔaroA} were used as this is the average CFU count obtained from the live infections after 24 hours, and the amount of SN added was also calculated based on this CFU.

Succinate Assay

Succinate assay (Sigma) was performed on cell lysates as per the manufacturers protocol and 96-well plates were measured on a spectrophotometer (Spectrostar Nano – BMG Labtech) at the respective wavelengths.

Supplementary Materials

Fig. S1. Mouse weight change during AOM/DSS CAC induction

Fig. S2: CFU in peripheral organs and SI 24 hours after *STm*^{ΔaroA} treatment

Fig. S3: Scanning electron microscopy of non-treated tumors.

Fig. S4: *STm*^{ΔaroA} treatment alters the transcriptional landscape of tumors

Fig. S5: Metabolomics analysis after 6 weeks *STm*^{ΔaroA} treatment *in vivo*

Fig. S6: Metabolomics analysis after 24 hours *STm*^{ΔaroA} treatment *in vivo*

Fig. S7: Metabolomics analysis after 24 hours *STm*^{ΔaroA} treatment *in vitro*

Table S1: List of metabolites with VIP score > 1 in tumors treated with *STm*^{ΔaroA} for 6 weeks

Table S2: List of metabolites with VIP score > 1 in tumors treated with *STm*^{ΔaroA} for 24 hours *in vivo*.

Table S3: List of metabolites with VIP score > 1 in tumor organoid cultures treated with *STm*^{ΔaroA} for 24 hours *in vitro*.

References:

1. E. F. McCarthy, The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, *Iowa Orthop J* **26**, 154–158 (2006).
2. A. B. Alexandroff, A. M. Jackson, M. A. O'Donnell, K. James, BCG immunotherapy of bladder cancer: 20 years on, *Lancet* **353**, 1689–1694 (1999).
3. N. S. Forbes, Engineering the perfect (bacterial) cancer therapy, *Nat. Publ. Gr.* **10** (2010), doi:10.1038/nrc2934.
4. K. Hayashi, M. Zhao, K. Yamauchi, N. Yamamoto, H. Tsuchiya, K. Tomita, H. Kishimoto, M. Bouvet, R. M. Hoffman, Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*, *Cell Cycle* **8**, 870–875 (2009).
5. M. Zhao, M. Yang, X. M. Li, P. Jiang, E. Baranov, S. Li, M. Xu, S. Penman, R. M. Hoffman, Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing *Salmonella typhimurium*, *Proc Natl Acad Sci U S A* **102**, 755–760 (2005).
6. M. Zhao, J. Geller, H. Ma, M. Yang, S. Penman, R. M. Hoffman, Monotherapy with a tumor-targeting mutant of *Salmonella typhimurium* cures orthotopic metastatic mouse models of human prostate cancer, *Proc Natl Acad Sci U S A* **104**, 10170–10174 (2007).
7. J. M. Pawelek, K. B. Low, D. Bermudes, Tumor-targeted *Salmonella* as a novel anticancer vector, *Cancer Res* **57**, 4537–4544 (1997).
8. T. Murakami, Y. Hiroshima, M. Zhao, Y. Zhang, T. Chishima, K. Tanaka, M. Bouvet, I. Endo, R. M. Hoffman, Therapeutic efficacy of tumor-targeting *Salmonella typhimurium* A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models, *Oncotarget* (2015) (available at <http://www.ncbi.nlm.nih.gov/pubmed/26375054>).
9. W. K. Wang, M. F. Lu, Y. D. Kuan, C. H. Lee, The treatment of mouse colorectal cancer by oral delivery tumor-targeting *Salmonella*, *Am J Cancer Res* **5**, 2222–2228 (2015).
10. J. F. Toso, V. J. Gill, P. Hwu, F. M. Marincola, N. P. Restifo, D. J. Schwartzentruber, R. M. Sherry, S. L. Topalian, J. C. Yang, F. Stock, L. J. Freezer, K. E. Morton, C. Seipp, L. Haworth, S. Mavroukakis, D. White, S. MacDonald, J. Mao, M. Sznol, S. A. Rosenberg, Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma, *J Clin Oncol* **20**, 142–152 (2002).
11. C. Cunningham, J. Nemunaitis, A phase I trial of genetically modified *Salmonella typhimurium* expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-

- fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001., *Hum. Gene Ther.* **12**, 1594–6 (2001).
12. J. Nemunaitis, C. Cunningham, N. Senzer, J. Kuhn, J. Cramm, C. Litz, R. Cavagnolo, A. Cahill, C. Clairmont, M. Sznol, Pilot trial of genetically modified, attenuated *Salmonella* expressing the *E. coli* cytosine deaminase gene in refractory cancer patients, *Cancer Gene Ther.* **10**, 737–744 (2003).
13. S. L. Coutermarsh-Ott, K. M. Broadway, B. E. Scharf, I. C. Allen, Effect of *Salmonella enterica* serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression., *Oncotarget* **8**, 33601–33613 (2017).
14. C. A. Silva-Valenzuela, P. T. Desai, R. C. Molina-Quiroz, D. Pezoa, Y. Zhang, S. Porwollik, M. Zhao, R. M. Hoffman, I. Contreras, C. A. Santiviago, M. McClelland, Solid tumors provide niche-specific conditions that lead to preferential growth of *Salmonella*, *Oncotarget* **7** (2016) (available at www.impactjournals.com/oncotarget).
15. R. W. Kasinskas, N. S. Forbes, *Salmonella typhimurium* lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis, *Cancer Res.* **67**, 3201–3209 (2007).
16. K. Crull, D. Bumann, S. Weiss, Influence of infection route and virulence factors on colonization of solid tumors by *Salmonella enterica* serovar Typhimurium, *FEMS Immunol Med Microbiol* **62**, 75–83 (2011).
17. K. Crull, M. Rohde, K. Westphal, H. Loessner, K. Wolf, A. Felipe-López, M. Hensel, S. Weiss, Biofilm formation by *Salmonella enterica* serovar Typhimurium colonizing solid tumours, *Cell. Microbiol.* **13**, 1223–1233 (2011).
18. Y. Hiroshima, M. Zhao, A. Maawy, Y. Zhang, M. H. G. Katz, J. B. Fleming, F. Uehara, S. Miwa, S. Yano, M. Momiyama, A. Suetsugu, T. Chishima, K. Tanaka, M. Bouvet, I. Endo, R. M. Hoffman, Efficacy of *Salmonella typhimurium* A1-R Versus Chemotherapy on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX), *J. Cell. Biochem.* **115**, 1254–1261 (2014).
19. S. Chowdhury, S. Castro, C. Coker, T. E. Hinchliffe, N. Arpaia, T. Danino, Programmable bacteria induce durable tumor regression and systemic antitumor immunity, *Nat. Med.* **25**, 1057–1063 (2019).
20. J. H. Zheng, V. H. Nguyen, S.-N. Jiang, S.-H. Park, W. Tan, S. H. Hong, M. G. Shin, I.-J. Chung, Y. Hong, H.-S. Bom, H. E. Choy, S. E. Lee, J. H. Rhee, J.-J. Min, Two-step enhanced cancer immunotherapy with engineered *Salmonella typhimurium* secreting heterologous flagellin., *Sci. Transl. Med.* **9**, eaak9537 (2017).
21. J.-E. Kim, T. X. Phan, V. H. Nguyen, H.-V. Dinh-Vu, J. H. Zheng, M. Yun, S.-G. Park, Y. Hong, H. E. Choy, M. Szardenings, W. Hwang, J.-A. Park, S. Park, S.-H. Im, J.-J. Min, *Salmonella typhimurium* Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1 β ., *Theranostics* **5**, 1328–42 (2015).
22. T. X. Phan, V. H. Nguyen, M. T.-Q. Duong, Y. Hong, H. E. Choy, J.-J. Min, Activation of inflammasome

- by attenuated *Salmonella typhimurium* in bacteria-mediated cancer therapy, *Microbiol. Immunol.* **59**, 664–675 (2015).
23. K. Westphal, S. Leschner, J. Jablonska, H. Loessner, S. Weiss, Containment of Tumor-Colonizing Bacteria by Host Neutrophils, *Cancer Res.* **68**, 2952–2960 (2008).
24. M. E. Sellin, A. A. Muller, B. Felmy, T. Dolowschiak, M. Diard, A. Tardivel, K. M. Maslowski, W. D. Hardt, Epithelium-Intrinsic NAIP/NLRC4 Inflammasome Drives Infected Enterocyte Expulsion to Restrict Salmonella Replication in the Intestinal Mucosa, *Cell Host Microbe* **16**, 237–248 (2014).
25. R. Allam, M. H. Maillard, A. Tardivel, V. Chennupati, H. Bega, C. W. Yu, D. Velin, P. Schneider, K. M. Maslowski, Epithelial NAIPs protect against colonic tumorigenesis, *J. Exp. Med.* **212**, 369–383 (2015).
26. M. M. Levine, R. E. Black, C. Ferreccio, R. Germanier, LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATION, *Lancet* **329**, 1049–1052 (1987).
27. P. A. Gulig, T. J. Doyle, The Salmonella typhimurium virulence plasmid increases the growth rate of salmonellae in mice., *Infect. Immun.* **61**, 504–11 (1993).
28. V. Fazio, M. Robertis, E. Massi, M. Poeta, S. Carotti, S. Morini, L. Cecchetelli, E. Signori, The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies, *J. Carcinog.* **10**, 9 (2011).
29. D. W. Huang, B. T. Sherman, R. A. Lempicki, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, *Nucleic Acids Res.* **37**, 1–13 (2009).
30. D. W. Huang, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, *Nat. Protoc.* **4**, 44–57 (2009).
31. A. Shvab, G. Haase, A. Ben-Shmuel, N. Gavert, T. Brabletz, S. Dedhar, A. Ben-Ze’ev, Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression., *Oncogene* **35**, 549–57 (2016).
32. J. Muñoz, D. E. Stange, A. G. Schepers, M. van de Wetering, B.-K. Koo, S. Itzkovitz, R. Volckmann, K. S. Kung, J. Koster, S. Radulescu, K. Myant, R. Versteeg, O. J. Sansom, J. H. van Es, N. Barker, A. van Oudenaarden, S. Mohammed, A. J. R. Heck, H. Clevers, The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers, *EMBO J.* **31**, 3079–3091 (2012).
33. D. Hirsch, N. Barker, N. McNeil, Y. Hu, J. Camps, K. McKinnon, H. Clevers, T. Ried, T. Gaiser, LGR5 positivity defines stem-like cells in colorectal cancer., *Carcinogenesis* **35**, 849–58 (2014).
34. N. Barker, R. A. Ridgway, J. H. van Es, M. van de Wetering, H. Begthel, M. van den Born, E. Danenberg, A. R. Clarke, O. J. Sansom, H. Clevers, Crypt stem cells as the cells-of-origin of intestinal cancer, *Nature* **457**,

608–611 (2009).

35. D. Leclerc, D. N. T. Pham, N. Lévesque, M. Truongcao, W. D. Foulkes, C. Sapienza, R. Rozen, Oncogenic role of PDK4 in human colon cancer cells, *Br. J. Cancer* **116**, 930–936 (2017).

36. A. Satelli, S. Li, Vimentin in cancer and its potential as a molecular target for cancer therapy, *Cell. Mol. Life Sci.* **68**, 3033–3046 (2011).

37. N. Makrilia, A. Kollias, L. Manolopoulos, K. Syrigos, Cell Adhesion Molecules: Role and Clinical Significance in Cancer, *Cancer Invest.* **27**, 1023–1037 (2009).

38. J. Xia, D. S. Wishart, J. Xia, D. S. Wishart, in *Current Protocols in Bioinformatics*, (John Wiley & Sons, Inc., Hoboken, NJ, USA, 2016), pp. 14.10.1–14.10.91.

39. J. Xia, I. V. Sinelnikov, B. Han, D. S. Wishart, MetaboAnalyst 3.0—making metabolomics more meaningful, *Nucleic Acids Res.* **43**, W251–W257 (2015).

40. A. Hirayama, K. Kami, M. Sugimoto, M. Sugawara, N. Toki, H. Onozuka, T. Kinoshita, N. Saito, A. Ochiai, M. Tomita, H. Esumi, T. Soga, Quantitative Metabolome Profiling of Colon and Stomach Cancer Microenvironment by Capillary Electrophoresis Time-of-Flight Mass Spectrometry, *Cancer Res* **69**, 4918–25 (2009).

41. A. Luengo, D. Y. Gui, M. G. Vander Heiden, Targeting Metabolism for Cancer Therapy., *Cell Chem. Biol.* **24**, 1161–1180 (2017).

42. L. Spiga, M. G. Winter, T. Furtado de Carvalho, W. Zhu, E. R. Hughes, C. C. Gillis, C. L. Behrendt, J. Kim, D. Chessa, H. L. Andrews-Polymenis, D. P. Beiting, R. L. Santos, L. V. Hooper, S. E. Winter, An Oxidative Central Metabolism Enables Salmonella to Utilize Microbiota-Derived Succinate, *Cell Host Microbe* **22**, 291–301.e6 (2017).

43. C. C. Gillis, E. R. Hughes, L. Spiga, M. G. Winter, W. Zhu, T. Furtado de Carvalho, R. B. Chanin, C. L. Behrendt, L. V Hooper, R. L. Santos, S. E. Winter, Dysbiosis-Associated Change in Host Metabolism Generates Lactate to Support Salmonella Growth., *Cell Host Microbe* **23**, 54–64.e6 (2018).

44. M. Loeffler, G. Le’Negrate, M. Krajewska, J. C. Reed, Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth., *Proc. Natl. Acad. Sci. U. S. A.* **104**, 12879–83 (2007).

45. S.-N. Jiang, T. X. Phan, T.-K. Nam, V. H. Nguyen, H.-S. Kim, H.-S. Bom, H. E. Choy, Y. Hong, J.-J. Min, Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli–mediated Cytolytic Therapy and Radiotherapy, *Mol. Ther.* **18**, 635 (2010).

46. M. O. Din, T. Danino, A. Prindle, M. Skalak, J. Selimkhanov, K. Allen, E. Julio, E. Atolia, L. S. Tsimring, S. N. Bhatia, J. Hasty, Synchronized cycles of bacterial lysis for in vivo delivery, *Nature* **536**, 81–85 (2016).

47. T. Chien, A. Doshi, T. Danino, Advances in bacterial cancer therapies using synthetic biology., *Curr. Opin.*

Syst. Biol. **5**, 1–8 (2017).

48. D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, S. L. Salzberg, TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions., *Genome Biol.* **14**, R36 (2013).

49. C. Trapnell, D. G. Hendrickson, M. Sauvageau, L. Goff, J. L. Rinn, L. Pachter, Differential analysis of gene regulation at transcript resolution with RNA-seq, *Nat. Biotechnol.* **31**, 46–53 (2013).

50. Y. Sato, K. Sakurai, H. Tanabe, T. Kato, Y. Nakanishi, H. Ohno, C. Mori, Maternal gut microbiota is associated with newborn anthropometrics in a sex-specific manner, *J. Dev. Orig. Health Dis.* , 1–8 (2019).

51. T. Sato, D. E. Stange, M. Ferrante, R. G. Vries, J. H. Van Es, S. Van den Brink, W. J. Van Houdt, A. Pronk, J. Van Gorp, P. D. Siersema, H. Clevers, Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium, *Gastroenterology* **141**, 1762–1772 (2009).

Acknowledgments: Thank you to David Bending, Haydn Munford, Adam Cunningham, Jeff Cole and Nobuo Sasaki for critical reading of the manuscript and suggestions. **Funding:**

KMM was supported by a RIKEN Programs for Young Scientists Foreign Postdoctoral Researcher Fellowship, and is currently supported by a CRUK CEA (C61638/A27112). The Japan Society for the Promotion of Science KAKENHI (19H01030) and Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (J15652274) awarded to HO also supported the work. **Author contributions:** KMM

conceived the project, designed and performed experiments throughout, analyzed data and wrote the manuscript. MT provided technical assistance throughout and maintained animal breeding. YN performed the GC-MS metabolomics experiments and analyzed data. GMM, IE and AC performed organoid experiments. HOd analysed RNAseq data. TK generated mCherry and GFP-expressing *STm^{ΔaroA}*, helped establish organoid expertise, and sought local experimental ethics authority. HO advised on the project, manuscript, and provided funding.

Competing interests: The authors declare no conflicts of interest. **Data and materials**

availability: RNAseq data is uploaded and available online (Gene Expression Omnibus: GSE136029).

Supplementary Materials:

Figure S1. Mouse weight change during AOM/DSS CAC induction

Mice were treated with AOM and DSS (See Figure 1A and methods) to induce colitis-associated cancer. Mouse weight was monitored over the induction period and mice allocated to treatment or non-treatment groups after the last dose of DSS, assuring similar DSS-induced weight change between groups. Mice represented here are the same group in Figure 1B.

Figure S2: CFU in peripheral organs and SI 24 hours after *STm*^{ΔaroA} treatment

Apc^{min/+} mice were given 5×10⁹ CFU of *STm*^{ΔaroA} by oral gavage and bacterial colonization was assessed 24 hours later. Blood, liver, spleen, mesenteric lymph nodes (MLN), normal (N) small intestinal (SI) tissue and SI tumors were dissected, homogenized in PBS – 0.1% triton-X and plated onto LB agar plates containing ampicillin.

Figure S3: Scanning electron microscopy of and immunohistochemistry of tumors.

(A) Mice bearing CAC colon tumors were given control vehicle by oral gavage and tissues were taken 24 hours later and prepared for SEM. (B) CAC tumor-bearing mice were treated for 6 weeks with mCherry-expressing STm^{ΔaroA}. Tissue sections were prepared for IHC. Red = STm^{ΔaroA}, Green = F-actin, Blue = DAPI.

Figure S4: *STmΔaroA* treatment alters the transcriptional landscape of tumors

A selection of differentially expressed genes (DEGs) identified by RNA sequencing. Tumors shows an increased expression of a range of gene associated with processes from cell cycle regulation, DNA repair to epithelial-to-mesenchymal transition. Many of these are reduced following *STmΔaroA* treatment.

Figure S5: Metabolomics analysis after 6 weeks *STm*^{ΔaroA} treatment *in vivo*
Top altered metabolites detected as described in figure 5.

Figure S6: Metabolomics analysis after 24 hours *STm*^{ΔaroA} treatment *in vivo*
Top altered metabolites detected as described in figure 5.

Figure S7: Metabolomics analysis after 24 hours *STm*^{ΔaroA} treatment *in vitro*
Top altered metabolites detected as described in figure 5.

Figure S8: Tumor organoid morphology and infection.

(A) Tumor organoids are grown as indicated in methods. Representative images of *Apc*^{min/+}-derived tumor organoids at D5 post-split before infection. (B) 24 hours post-infection with GFP-expressing *STm*^{ΔaroA}, brightfield overlaid with GFP, (C) 24 hours control treated, brightfield overlaid with GFP.

Table S1: List of metabolites with VIP score > 1 in tumors treated with *STm^{ΔaroA}* for 6 weeks.

Name	VIP score	fold change	P value
Glycerol	1.9801	0.8329	0.0163
2'-Deoxyuridine	1.9727	0.7054	0.0268
Lactic acid	1.9058	0.7767	0.0231
Urea	1.9031	1.3869	0.0234
7-Methylguanine	1.8888	1.4163	0.0250
Cytosine	1.8837	0.7140	0.0255
Tryptamine	1.8638	0.6275	0.0278
Arabitol	1.8477	0.4773	0.0297
Threonic acid	1.8113	1.5825	0.0345
2-Deoxy-glucose	1.7847	1.5725	0.0382
Glyoxylic acid	1.7838	0.6815	0.0383
Guanine	1.7717	1.4754	0.0401
Succinic acid	1.7699	0.3128	0.0404
Glycolic acid	1.7492	1.3657	0.0436
Creatinine	1.7423	0.6650	0.0448
Hippuric acid	1.7407	0.8170	0.0450
Putrescine	1.6135	0.7501	0.0691
Dimethylglycine	1.6076	0.6924	0.0704
3-Aminoisobutyric acid	1.5878	1.9660	0.0748
3-Aminopropanoic acid	1.5855	0.7546	0.0754
Xylose	1.5652	2.2137	0.0801
Ornithine	1.5272	0.6445	0.0895
5-Aminovaleric acid	1.5222	4.8578	0.0908
Indol-3-acetic acid	1.4590	1.6265	0.1081
Cellobiose	1.4068	1.6114	0.1238
Xanthosine	1.3765	1.7125	0.4535
3-Hydroxyglutaric acid	1.3594	0.8171	0.1393
Malic acid	1.3564	0.8042	0.1403
Glycyl-Glycine	1.3298	0.8518	0.1495
Sarcosine	1.3274	2.5237	0.1504
Allantoin	1.3171	1.3080	0.1540
Methionine	1.2888	1.6375	0.1644
Galactosamine	1.2835	0.7079	0.1664
Galactose	1.2715	0.7943	0.1710
Psicose	1.2256	0.7198	0.1891
Azelaic acid	1.2253	2.3617	0.1892
Norepinephrine	1.2137	1.4135	0.1940
Maltose	1.1786	0.6873	0.2087
Thymine	1.1628	0.7944	0.2156
O-Acetylserine	1.1543	0.7792	0.2193
Fucose	1.1515	1.5400	0.2206
Glucono-1,5-lactone	1.1514	0.8112	0.2206
Mannose	1.1222	0.8146	0.2338
Dihydrouracil	1.1212	0.3632	0.2527
Lyxose	1.1023	1.2183	0.2430
Lactitol	1.1004	0.1406	0.2469
3-Hydroxybutyric acid	1.0600	0.7720	0.2634
Fructose	1.0328	0.8219	0.2769
Phosphoric acid	1.0182	0.9116	0.2843
Hypotaurine	1.0104	0.6991	0.2883
2-Aminoadipic acid	1.0064	1.3342	0.2904

Table S2: List of metabolites with VIP score > 1 in tumors treated with *STm*^{ΔaroA} for 24 hours in vivo.

Metabolite	VIP score	fold change	P value
Inosine monophosphate	1.9117	0.2165	0.0031
Ribitol	1.9078	0.5208	0.0032
Cellobiose	1.8644	0.3229	0.0049
Arabitol	1.8548	0.5605	0.0054
Citric acid	1.8209	0.6098	0.0072
Trehalose	1.8013	0.3828	0.0084
Maltose	1.7993	0.4144	0.0085
Glucose	1.7758	0.4263	0.0101
Fumaric acid	1.7675	0.7185	0.0108
Isomaltose	1.7439	0.5221	0.0337
Dimethylglycine	1.7136	0.5386	0.0154
Lactulose	1.7134	0.6199	0.0155
Spermidine	1.7116	0.4437	0.0156
Hypotaurine	1.6867	0.3729	0.0182
3-Hydroxyisobutyric acid	1.6852	0.5794	0.0184
Lactitol	1.682	0.318	0.0187
5-Oxoproline	1.6626	0.7883	0.021
Xanthosine monophosphate	1.5912	0.624	0.0307
Xylitol	1.5887	0.4935	0.0311
Dihydroxyacetone phosphate	1.5866	0.6799	0.0314
Galactitol	1.5846	0.697	0.0317
Malic acid	1.582	0.7039	0.0321
3-Aminopropanoic acid	1.508	0.6303	0.0453
Cystathionine	1.5071	0.2898	0.0455
2-Hydroxyglutaric acid	1.5053	0.653	0.0459
Ornithine	1.4971	0.5365	0.0475
Cystine	1.4846	0.1547	0.041
Orotic acid	1.4598	0.5003	0.0555
O-Phosphoethanolamine	1.4504	0.7158	0.0576
Mannitol	1.4501	0.6358	0.0577
Succinic acid	1.4359	0.6271	0.061
Adenine	1.4174	0.6324	0.0656
Galactose	1.4101	0.6707	0.0674
Glucono-1,5-lactone	1.409	0.6451	0.0677
4-Hydroxyproline	1.4049	0.655	0.0688
Glucosamine	1.4024	1.54	0.0694
Glycine	1.3736	0.6654	0.0771
2,3-Bisphosphoglyceric acid	1.3672	1.6316	0.0789
Threonine	1.3359	0.7095	0.088
Glycerol 3-phosphate	1.3344	4.6072	0.0884
Cadaverine	1.3212	0.7518	0.0925
Glutamic acid	1.3211	0.7397	0.0925
Lactic acid	1.3108	0.8793	0.0956
Glycerol 2-phosphate	1.3081	1.7895	0.0966
Norvaline	1.3072	0.4694	0.0969
Cystamine	1.2993	0.5627	0.0994
Threonic acid	1.2797	0.764	0.1059
Lysine	1.2702	0.6183	0.1091
Phosphoenolpyruvic acid	1.2513	1.3313	0.2217
Tryptophan	1.2467	0.4	0.1173
Tyramine	1.242	0.6351	0.119
Arginine	1.242	0.6349	0.119
Ethylmalonic acid	1.2372	1.5596	0.1207

Erythrose 4-phosphate	1.2264	0.5996	0.1247
Ureidosuccinic acid	1.2199	0.7154	0.1271
Niacinamide	1.2189	0.8437	0.1275
Histidine	1.2025	0.6424	0.1338
Allantoin	1.1996	0.5463	0.1349
Proline	1.1976	0.736	0.1357
Ribonic acid	1.1963	0.736	0.1362
2-Aminoadipic acid	1.1784	0.6401	0.1433
Pyruvic acid	1.1765	0.8362	0.1441
6-Phosphogluconic acid	1.1526	0.4985	0.1539
Oleamide	1.1515	0.4691	0.1544
Hydroquinone	1.1409	0.67	0.1588
2-Aminoisobutyric acid	1.1385	1.9668	0.1599
N-Acetylserine	1.1154	0.7525	0.17
Norepinephrine	1.1102	1.2179	0.1723
Taurine	1.1045	0.8301	0.1748
Mannose 6-phosphate	1.1003	0.7004	0.1768
4-Aminobutyric acid	1.0925	0.789	0.1803
Glutamic acid 5-methylester	1.0873	1.3579	0.1827
Glucose 6-phosphate	1.0682	0.7218	0.1917
Quinolinic acid	1.0502	0.0916	0.2003
2-Phosphoglyceric acid	1.0498	1.6942	0.1907
Aspartic acid	1.0399	0.8244	0.2054
Allose	1.0192	0.7538	0.2158
Glucaric acid	1.0118	0.663	0.1895
N-Acetylneuraminic acid	1.005	0.827	0.2231

Table S3: List of metabolites with VIP score > 1 in tumor organoids treated with *STm^{ΔaroA}* for 24 hours.

Metabolite	VIP score	fold change	P value
Inositol	1.8382	0.4290	0.0178
2'-Deoxyuridine	1.8269	5.1418	0.0195
Phenylacetic acid	1.7964	0.4992	0.0247
Coniferyl alcohol	1.7576	8.5705	0.0320
Homovanillic acid	1.7155	0.4414	0.0410
Lactic acid	1.7002	0.6143	0.0492
O-Phosphoethanolamine	1.6650	0.5077	0.0532
Fucose	1.6605	3.1011	0.0543
Indol-3-acetic acid	1.6476	0.7028	0.0577
Taurine	1.6293	1.6209	0.0626
5-Aminolevulinic acid	1.5572	0.4599	0.0839
Uridine	1.5306	2.1723	0.1633
Lyxose	1.5002	0.5528	0.1026
Dimethylglycine	1.4973	0.5974	0.1036
Galactose	1.4862	2.2448	0.1075
Malic acid	1.4547	0.6259	0.1188
Arginine	1.4504	0.6035	0.1204
Ribonic acid	1.4259	0.2950	0.1295
4-Aminobenzoic acid	1.4205	0.5189	0.1316
Hypotaurine	1.4123	0.5822	0.1348
Threonic acid	1.4033	0.5742	0.1383
Mannitol	1.3841	3.2098	0.1437
Spermidine	1.3798	3.1311	0.1476
Glyoxylic acid	1.3191	0.6411	0.1729
Sebacic acid	1.3114	0.6055	0.1762
Guanine	1.2997	2.1673	0.1813
Homocysteine	1.2973	2.7287	0.1824
2-Aminoethanol	1.2938	0.7175	0.1839
Phosphoenolpyruvic acid	1.2811	1.5814	0.1895
Suberic acid	1.2801	0.3291	0.1900
Serine	1.2790	0.7142	0.1905
Pantothenic acid	1.2545	0.7354	0.2016
3-Aminopropanoic acid	1.1723	0.7260	0.2407
Xylose	1.1591	3.2897	0.2472
Alanine	1.1475	1.4680	0.2530
Arabitol	1.1097	3.7650	0.2723
Glucose	1.1063	3.0801	0.5069
Sorbitol	1.1018	3.1654	0.5090
Tyrosine	1.0957	2.4572	0.2795
Pyruvic acid	1.0729	0.6639	0.2915
Fumaric acid	1.0709	0.6866	0.2926
Dodecanedioic acid	1.0598	0.6416	0.2985
3-Hydroxypropionic acid	1.0470	0.6421	0.3054
2-Hydroxyglutaric acid	1.0444	0.6318	0.3068
Ribose	1.0413	1.6181	0.3085
Pyridoxamine	1.0286	2.3168	0.3154
Glutaric acid	1.0275	0.3534	0.3160
Ureidopropionic acid	1.0198	0.5835	0.3202
Dopa	1.0162	1.7613	0.3222
Adenine	1.0124	1.6859	0.3243
Hypoxanthine	1.0080	5.7728	0.3267
4-Aminobutyric acid	1.0006	1.7863	0.3308